The U.S. is seeing a substantial rise in subcutaneous implantable cardioverter defibrillator (ICD) use, a national registry suggests. Compared with those receiving single- and dual-chamber devices, patients receiving the subcutaneous alternative were more likely to be younger, female, black, undergoing dialysis, and have a history of cardiac arrest.
A premixed vial of tirofiban hydrochloride (Aggrastat) will be available later in the U.S. this year, thanks to FDA approval. Before the new mixing and packaging, the glycoprotein IIb/IIIa inhibitor had already been green-lighted for patients with non-ST segment elevation acute coronary syndrome.
Two Trevo clot-grabbing devices were granted an expanded indication to include patients also receiving thrombolysis, the FDA announced. In 2012, the agency had cleared the devices for use in patients who were resistant to or could not receive tissue plasminogen activator.
Published results from the OASIS trial were retracted from the Journal of the American College of Cardiology following complaints regarding the study’s randomization process and the timing of patient enrollment. “Another victory of the industry and their conflicted accolades,” tweeted lead author Andrea Natale, MD, of Texas Cardiac Arrhythmia in Austin, in response to the retraction. OASIS had originally reported that rotor ablation was not as good as conventional radiofrequency ablation for persistent atrial fibrillation.
In heart failure patients with ICDs, exercise training was deemed safe by study authors who noted that it was also tied to better cardiorespiratory fitness and a lower risk of device shocks.
Obese patients were no more likely to die while on left ventricular assist device support than their peers with normal BMIs. However, those in class II or greater had higher odds of complications requiring them to skip ahead in the heart transplant waiting list.
For cardioversion in the setting of recent onset Afib, the novel oral anticoagulant edoxaban (Savaysa) worked just as well as the standard regimen of warfarin/enoxaparin, according to the ENSURE-AF investigators at the European Society of Cardiology meeting in Rome.